Evidence map›Paper›PMID 29287664›Full record

ArticleContemporary clinical trials2018

A sequential multiple assignment randomized trial for cocaine cessation and relapse prevention: Tailoring treatment to the individual.

Joy M Schmitz, Angela L Stotts, Anka A Vujanovic, Michael F Weaver, Jin H Yoon, Jessica Vincent, Charles E Green

Abstract readClinical Trial Protocol
In one paragraph

Article in Contemporary clinical trials, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Baseline cocaine demand predicts contingency management treatment outcomes for cocaine-use disorder.Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Joy M SchmitzDepartment of Psychiatry & Behavioral Sciences, McGovern Medical School, University of Texas Health Science Center at Houston, United States. Electronic address: Joy.M.Schmitz@uth.tmc.edu.
Angela L StottsDepartment of Psychiatry & Behavioral Sciences, McGovern Medical School, University of Texas Health Science Center at Houston, United States; Department of Family and Community Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, United States.
Anka A VujanovicDepartment of Psychology, University of Houston, United States.
Michael F WeaverDepartment of Psychiatry & Behavioral Sciences, McGovern Medical School, University of Texas Health Science Center at Houston, United States.
Jin H YoonDepartment of Psychiatry & Behavioral Sciences, McGovern Medical School, University of Texas Health Science Center at Houston, United States.
Jessica VincentDepartment of Psychiatry & Behavioral Sciences, McGovern Medical School, University of Texas Health Science Center at Houston, United States.
Charles E GreenDepartment of Psychiatry & Behavioral Sciences, McGovern Medical School, University of Texas Health Science Center at Houston, United States; UT-Houston Center for Clinical Research & Evidence-Based Medicine, United States.

Funding

Translational MR Imaging in Cocaine Pharmacotherapy DevelopmentP50DA009262 · NIDA · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MOELLER, FREDERICK GERARD · 1994 to 2014
$26.9M
Developing Adaptive Interventions for Cocaine Cessation and Relapse PreventionR01DA039125 · NIDA · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI SCHMITZ, JOY MARIE · 2016 to 2019
$1.9M
NIDA NIH HHS P50 DA009262NIDA NIH HHS R01 DA039125
6 · The paper itself

Abstract

Drug addiction is a chronic, devastating, but treatable disorder. A core principle of drug addiction treatment states that no single treatment is appropriate for everyone (NIDA, 2012); treatments need to adjust based on patient characteristics and response in order to be maximally effective. For cocaine use disorders (CUD), specifically, the most potent intervention currently available for initiating abstinence is behavior therapy using contingency management (CM) procedures, with early cessation being a robust predictor of future abstinence. This raises two key questions for treatment development research: First, can we significantly improve initial CM response rates with targeted adjunctive interventions? Second, for individuals who fail to achieve initial abstinence with CM, is pharmacotherapy an effective augmentation strategy? This paper describes how a sequential, multiple assignment, randomized trial (SMART) design has advantages over a fixed-intervention approach when it comes to collecting data needed to answer both questions. The first aim will examine whether Acceptance and Commitment Therapy (ACT) in combination with CM increases initial abstinence response rates (i.e., 2 consecutive weeks of cocaine-negative urine screens). The second aim will examine whether ACT+CM in combination with modafinil promotes abstinence achievement in initial non-responders. Results are expected to inform how we tailor treatment of CUD to maximize outcomes.

Indexed as

Behavior TherapyCocaine-Related DisordersAdolescentAdultCentral Nervous System StimulantsFemaleHumansMaleMiddle AgedModafinilPatient Care PlanningRandomized Controlled Trials as TopicYoung AdultCentral Nervous System StimulantsModafinilAcceptance and Commitment Therapy (ACT)Bayesian approachCocaine use disorderContingency management (CM)ModafinilMultiple assignmentRandomized trial (SMART)Sequential

Identifiers

PMID29287664
PMCPMC5803345

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.